Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
The precise mechanism by which erastin inhibits
2022-08-02
The precise mechanism by which erastin inhibits SLC7A11-mediated cystine import it still unknown. The initially proposed mechanism, by which erastin binds a related transport protein, SLC7A5, and inhibits SLC7A11 in trans [25], was revised soon after, and it was suggested that erastin inhibits SLC7A
-
Although unexpected based on our
2022-08-02
Although unexpected based on our predictions, low baseline and post-stress cortisol being associated with high anxiety has been previously documented in both clinical and healthy populations of humans (Beaton et al., 2006; Jezova et al., 2004; Shirotsuki et al., 2009; Vingerhoets et al., 1996), and
-
Two recently developed highly specific EZH enzymatic inhibit
2022-08-02
Two recently developed, highly specific EZH2 enzymatic inhibitors, GSK126 and EPZ-6438, are currently in clinical trials for treating lymphomas (Kim and Roberts, 2016). Although these EZH2 inhibitors have shown antitumor effects in lymphoma cells with enzyme-activating mutations of EZH2 (Knutson et
-
In conclusion while class I HDAC inhibitors isoform specific
2022-07-30
In conclusion, while class I HDAC inhibitors, isoform-specific HDAC3 and HDAC6 inhibitors may represent novel therapeutic targets for prevention of clinical AF onset and progression, the specific HDAC3 and HDAC6 inhibitors may be more appropriate because of their limited off-targets effects. Besides
-
E E evolution at transmission
2022-07-30
E1E2 evolution at transmission has been explored in multiple previous studies. Vertical transmission selects for E1E2 variants with increased replication fitness due of CTL escape mutations (Honegger et al., 2013). Experimental infection of chimeric liver mice selects for E1E2 variants with increase
-
br Materials and methods br Results br Discussion
2022-07-30
Materials and methods Results Discussion I have identified an alternative transcript of the integrin αE gene that is abundantly expressed in testis. In humans, this transcript (hAED) includes part of intron 26 and exons 27, 29, 30, and 31 of the conventional αE gene and Northern analysis in
-
In conclusion these data in combination with previously desc
2022-07-30
In conclusion, these data in combination with previously described reports of GC-B being inactivated by dephosphorylation in response to other signaling molecules, strongly suggests that distinct hormonal systems inactivate GC-B by a general dephosphorylation mechanism. Identification of the modifi
-
Pam3CSK4 Biotin br Introduction Excitatory pyramidal neurons
2022-07-30
Introduction Excitatory pyramidal neurons are generated in the cortical ventricular zone and migrate into the cortical plate alongside the radial glial processes (Chanas-Sacre et al., 2000, Hartfuss et al., 2001, Noctor et al., 2001, Rakic, 1972, Tan et al., 1998). Neuronal migration determines t
-
GSK is inhibited by serine phosphorylation at a residue its
2022-07-30
GSK-3 is inhibited by serine Pam3CSK4 Biotin at a residue its N-terminus (Ser 9 in GSK-3β and Ser 21 in GSK-3α) [52], [53], [54]. This raised the possibility that the N-terminal tail may function as a pseudo-substrate by mimicking the pre-phosphorylated substrate. The interaction mode of the pseudo
-
An alternative approach to improving pharmacokinetic profile
2022-07-29
An alternative approach to improving pharmacokinetic profile while retaining high GlyT1 potency was also pursued. Libraries were prepared in which potency enhancing piperidine C4 substituents were combined with clearance lowering truncated alkyl sulfonamides. The result was the discovery of (). Unl
-
In conclusion we demonstrated that the atypical high basal
2022-07-29
In conclusion, we demonstrated that the atypical high-basal activity of the mGlu3 2-APB receptor results mostly from its activation by low ambient glutamate concentrations. This is due to a unique interaction network located in the extracellular domain of the mGlu3 receptor. This network acts as “C
-
br Origin of the vertebrate hexokinase
2022-07-29
Origin of the vertebrate hexokinase gene family Multiple hexokinases have been found in vertebrates, plants and yeast (Wilson, 1995, Cárdenas et al., 1998). A hexokinase in both vertebrates and yeast has, unfortunately, been named glucokinase. The sharing of the name glucokinase has suggested to
-
The mechanism underlying the anorectic effect of OXM is well
2022-07-29
The mechanism underlying the anorectic effect of OXM is well established. It is centrally mediated via GLP-1 receptor activation, confirmed by both pharmacological blockade of the GLP-1 receptor, and using GLP-1 receptor knock-out mice [2], [11], [12]. However, the mechanism by which it increases en
-
gpr40 agonist In perimenstrual catamenial epilepsy there
2022-07-29
In perimenstrual catamenial epilepsy, there is emerging evidence to suggest that P withdrawal plays a key role in seizure exacerbations occurring around the time of menstruation (Backstrom et al., 1984, Bonuccelli et al., 1989, Scharfman and MacLusky, 2006). The mechanisms underlying ovarian cycle-r
-
There are additional implications of subunit alterations in
2022-07-29
There are additional implications of α2-subunit alterations in the hippocampus. P has anticonvulsant activity (Herzog, 1995, Herzog et al., 1997, Herzog et al., 2012, Reddy et al., 2001, Reddy, 2010). These actions result from the metabolic conversion of P to GABA-A receptor-modulating, antiseizure
15949 records 388/1064 page Previous Next First page 上5页 386387388389390 下5页 Last page